Investigational Studies

Slowly but surely, it looks like the answer to that question is yes—for medicinal purposes, at least. As marijuana becomes more accepted by the law and society at large in the United State, the major professional sports have been moving towards a more permissive and open direction towards marijuana use, albeit at a glacial pace. […]

by

GW Pharmaceuticals (NASDAQ:GWPH) stock increased 2.08% or $2.30 November 3, reaching $113.12 following news that its cannabidiol-based drug candidate Epidiolex has been formally submitted to the Food and Drug Administration for review. If approved, it will allow GW to market Epidiolex in the U.S. The stock has risen 31.90% since November 5, 2016, outperforming the […]

by

GW Pharmaceuticals (NASDAQ:GWPH) stock increased 2.08% or $2.30 November 3, reaching $113.12 following news that its cannabidiol-based drug candidate Epidiolex has been formally submitted to the Food and Drug Administration for review. If approved, it will allow GW to market Epidiolex in the U.S. The stock has risen 31.90% since November 5, 2016, outperforming the […]

by

By Alicia Wallace, The Cannabist Staff A CBD-based pharmaceutical drug in development is one more step closer to potential FDA approval. Earlier this week, London-based GW Pharmaceuticals plc, which operates in the United States as Greenwich Biosciences, wrapped up its New Drug Application for Epidiolex, a formulation of the cannabis compound cannabidiol (CBD) for the […]

by

By Alicia Wallace, The Cannabist Staff A CBD-based pharmaceutical drug in development is one more step closer to potential FDA approval. Earlier this week, London-based GW Pharmaceuticals plc, which operates in the United States as Greenwich Biosciences, wrapped up its New Drug Application for Epidiolex, a formulation of the cannabis compound cannabidiol (CBD) for the […]

by

SAN DIEGO, Oct. 20, 2017 (GLOBE NEWSWIRE) — Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead molecule, EHP-101, for the treatment of systemic scleroderma. This chronic autoimmune disease causes severe fibrosis of […]

by

SAN DIEGO, Oct. 20, 2017 (GLOBE NEWSWIRE) — Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead molecule, EHP-101, for the treatment of systemic scleroderma. This chronic autoimmune disease causes severe fibrosis of […]

by

According to a forecast report by Arcview Market Research, growth in the legal cannabis market will re-accelerate in the beginning of 2018, as adult use (recreational use) sales are expected to ramp up in Canada, California, and Massachusetts along with medical sales in Florida. The market is expected to grow from the $6.7 billion market […]

by

TORONTO, ONTARIO–(Marketwired – Sept. 27, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation […]

by

By Alicia Wallace, The Cannabist Staff Cannabidiol is a non-psychoactive cannabis compound touted for its medicinal promise — but marijuana- and hemp-derived extracts rich in CBD and low in intoxicating THC are facing a future yet to be determined. The Cannabist’s special report “CBD, TBD” explores the issues with CBD — federal-state conflicts, national drug […]

by

A market report by Ameri Research Inc. indicates that the global legal cannabis market was valued at $14.3 billion in 2016 and is projected to grow at a CAGR of 21.1% from 2017 to 2024. During the forecast period, the projected demand of cannabis will continue to rise for both recreational and medical use with estimated global […]

by